CEL-SCI Corporation Releases Letter to Sh...(cessary to activate protective T cell im...),Health

Date:10/5/2009

cessary to activate protective T cell immune responses including killer T cells. This unique action promotes the production of inducer cytokines without the tissue damage and flu-symptom promoting cytokines (pro-inflammatory cytokines), tumor necrosis factor alpha or interleukin 1. This helps prevent or get around the issue of cytokine storm in which the production of too many pro-inflammatory cytokines contributes to the clinical decline and death of the patient. The activated dendritic cells seek out T cells that are specific for H1N1 influenza, present the influenza protein to them with the appropriate cytokines to get them excited, increase their numbers so that they can attack the infected cells with minimal peripheral damage.

The dendritic H1N1 treatment customizes the anti- influenza power of the LEAPS influenza technology. In short, the dendritic H1N1 treatment causes the maturation of monocyte white blood cells into dendritic cells that can direct and activate the subsequent immune response against H1N1 infected cells with minimal peripheral damage.

End of Dr. Rosenthal's explanation.

We are currently moving forward as fast as is possible with our proposed dendritic H1N1 treatment for hospitalized H1N1 patients, while proceeding with due caution and taking all necessary steps to meet regulatory requirements. The virus was only discovered 6 months ago and already we are embarking upon our initial clinical trial.

With regard to our investigational cancer medicine Multikine, we are preparing to commence the global Phase III clinical trial designed to support marketing approval. The validation of our new manufacturing facility for contract manufacturing operations is nearing completion, and we have expanded that validation to cover the manufacturing of Multikine in the new manufacturing facility as well.

From my perspective, we are in the best condi
'/>"/>

SOURCE CEL-SCI Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
2. CEL-SCI Expands H1N1 Flu Virus Work
3. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
4. CEL-SCI Posts New Corporate Presentation to Website
5. CEL-SCI Corporation Releases Letter to Shareholders
6. CEL-SCI Corporation Releases Letter to Shareholders
7. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
8. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
9. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Corporation Reports First Quarter Financial Results